No Detail Found!

Systemic In ammatory Markers for Prediction of Bevacizumab Bene t in Glioblastoma Multiforme

Author(s)
Mehmet Besiroglu Department of Medical Oncology, Bezmialem Vakif University, School of Medicine Hospital,Istanbul,Turkey
Abdallah TM Shbair Department of Medical Oncology, Bezmialem Vakif University, School of Medicine Hospital,Istanbul,Turkey
Ayse Irem Yasin Department of Medical Oncology, Bezmialem Vakif University, School of Medicine Hospital,Istanbul,Turkey
Atakan Topcu Department of Medical Oncology, Bezmialem Vakif University, School of Medicine Hospital,Istanbul,Turkey
Haci Mehmet Turk Department of Medical Oncology, Bezmialem Vakif University, School of Medicine Hospital,Istanbul,Turkey
Tarik Demir Department of Medical Oncology, Haydarpa_a Numune Health Application and Research Center,Istanbul,Turkey
Abstract
Objective: To evaluate the predictive signi cance of systemic in ammation markers (SIMs) in patients with glioblastoma multiforme (GBM), who were treated with bevacizumab (Beva). Study Design: Descriptive study. Place and Duration of Study: The study was conducted at the Bezmialem Vakif University School of Medicine Hospital, Istanbul, Turkey, from January 2014 to September 2019. Methodology: A total of 107 patients, 49 (45.8%) female and 58 (54.2%) male, were retrospectively included in the study. The cut-o values for the SIMs C-reactive protein to albumin ratio (CAR), neutrophil to lymphocyte (NLR) platelet to lymphocyte ratio (PLR), and systemic immune-in ammatory index (SIII)) were de ned by receiver operating characteristic (ROC) analysis. Overall survival (OS) was plotted using the Kaplan-Meier method and compared using the log-rank test. Cox regression analysis was performed for univariate and multivariate analyses. Results: ROC analysis was performed to determine the optimal prognostic value of each parameter. CAR: 1.32, NLR: 2.9, PLR: 159, and SIII: 785 were determined as cut-o values for predicting OS based on the areas under the curve (AUC) in the ROC analysis. CAR at 0.626, had sensitivity of 67%, and speci city of 71% (p=0.129); NLR at 0.725 had sensitivity of 67%, and speci city of 79% (p=0.007); PLR at 0.675 had sensitivity of 67%, and speci city of 64% (p=0.036); and SIII at 0.685, had sensitivity of 56%, and speci city of 71% (p=0.026). A multivariate analysis demonstrated that CAR (p=0.006) and PLR (p=0.024) were independent prognostic factors for OS in patients with GBM, treated by Beva. Conclusion: The present study's ndings suggest that pretreatment CAR and PLR might be an independent predictive marker for patients with GBM, who are treated by Beva.
Publication Details
Page(s) 39-44
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 31, Issue: 1, Year: 2021

Request the full text from PASTIC

Keywords
glioblastoma multiforme, Platelet-to-lymphocyte ratio (PLR), Neutrophil-to-lymphocyteratio (NLR), Predictive score, C-reactive protein-to-albumin ratio (AR)
0

Citations

0

Downloads

132

Views